Ig NextGen 10% in Idiopathic Thrombocytopenic Purpura (ITP) Patients
NCT00362349
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
19
Enrollment
INDUSTRY
Sponsor class
Conditions
Idiopathic Thrombocytopenic Purpura (ITP)
Interventions
DRUG:
IgNextGen 10%
Sponsor
CSL Limited